EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

Recruiting now

Conditions studied: NSCLC (Advanced Non-small Cell Lung Cancer)

In brief

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

Key facts

Study ID

NCT07096258

Run by

Hedera Dx SA

People needed

1000

Starts

2024-06-01

Expected to finish

2031-12-01

Last updated by the study team

2025-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease.
• Intention-to-initiate first-line tumour therapy for this advanced disease.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.

You may not qualify if…

• Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

Where it is running

• Université de Lorraine — Nancy, Lorraine, France (enrolling)
• University of Naples "Federico II" — Naples, Italy (enrolling)
• Hôpitaux Universitaires Genève — Geneva, Canton of Geneva, Switzerland (enrolling)
• General Universitario Gregorio Marañon — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.